CCHFVaccine, initially planned as a six-year project launched in January 2017 and coordinated by Folkhälsomyndigheten (the Public Institute of Sweden, FoHM, Professor Ali Mirazimi) in Sweden, has now been extended to eight years.
This extension aims to ensure the successful launch of a phase 1 trial in humans. Consequently, the project end date is now set for December 2024.
It's worth noting that there is already confirmation of a continuation project, known as CCHFVACIM.
Our collaborative network brings together 14 complementary partners, including 13 research institution and one technology transfer / management company.
The project is supported by the European Commission under the H2020 Programme
American continent
